-
Mashup Score: 4Tyrosine kinase inhibitor: An alternative treatment for non–small-cell lung cancer metastasis to the choroid - 2 hour(s) ago
Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment outcomes after targeted therapy compared with conventional radiotherapy and/or chemotherapy.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 5Harrow launches Harrow Cares program in partnership with Cencora - 6 hour(s) ago
The program will deliver a range of high-quality access and affordability services for retina specialists.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Harrow announced the launch of its “Harrow Cares” program in partnership with Cencora. The program will deliver a range of high-quality access and affordability services, strengthening support for retina specialists, their staff and patients. https://t.co/Z6kY6ETLlA
-
-
Mashup Score: 3Apellis Pharmaceuticals receives approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy in Australia - 11 hour(s) ago
The approval of Syfovre makes it the first and only approved treatment for GA in Australia.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Apellis has announced the Therapeutic Goods Administration in Australia has approved pegcetacoplan (Syfovre) for the every-other-month treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). https://t.co/pZpGlK77cm
-
-
Mashup Score: 2ARVO Foundation reveals 2025 Dr David L Epstein Award recipients - 15 hour(s) ago
Recipients will be awarded $100,000 to support a collaborative project related to glaucoma
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
The ARVO Foundation recently announced its 2025 recipients of the Dr. David L. Epstein Award. Recipients will be awarded $100,000 to support a collaborative project related to glaucoma https://t.co/UFKSQ9GrJf
-
-
Mashup Score: 3Norlase receives FDA 510(k) clearance and CE mark for LYNX pattern scanning laser indirect ophthalmoscope - 22 hour(s) ago
The company states LYNX is the world’s first and only pattern scanning laser indirect ophthalmoscope and is battery-powered to provide surgeons with an untethered laser solution.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Norlase, a leading global ophthalmic laser manufacturer, announced the immediate commercial launch and FDA 510(k) clearance and CE Mark for Norlase LYNX. https://t.co/WGZd6LFOHw
-
-
Mashup Score: 6
Chen and colleagues conducted a longitudinal study that included patients with high myopia who were followed for 10 years. Detailed ophthalmic examinations were conducted at the baseline and follow-up visits that included measurements of the BCVA and visual fields in 568 eyes of 284 patients.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
A new study of Chinese children and adults that investigated the effects of progression of myopia found that over the course of 10 years the BCVA and the visual function decreased, with an increasing incidence rate of moderate and severe visual impairment https://t.co/F4KKYYkzbv
-
-
Mashup Score: 3
The “Triangle sign” seen on ultrasound is a “distinctive and reliable” ultrasound feature for differentiating total choroidal detachments and suprachoroidal hemorrhages.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Researchers described that the “Triangle sign” seen on ultrasound is a “distinctive and reliable” ultrasound feature for differentiating total choroidal detachments (CHs) and suprachoroidal hemorrhages (SCHs) https://t.co/WoJzZEiwhb
-
-
Mashup Score: 4Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome - 1 day(s) ago
The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the genetic defects in the BBS1 gene.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Viralgen and Axovia Therapeutics are partnering to advance the development and manufacture of an AAV9-based investigational gene therapy aimed at treating retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) https://t.co/jp6WqXTECM
-
-
Mashup Score: 5Tyrosine kinase inhibitor: An alternative treatment for non–small-cell lung cancer metastasis to the choroid - 2 day(s) ago
Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment outcomes after targeted therapy compared with conventional radiotherapy and/or chemotherapy.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
A Chinese study found that a tyrosine kinase inhibitor achieved both durable disease control and visual improvement in patients with epidermal growth factor receptor mutation-positive non–small-cell lung carcinoma that had metastasized to the choroid. https://t.co/MmFoP37c6M
-
-
Mashup Score: 5
Funds from the Inasmuch Foundation and The Samuel Roberts Noble Foundation will support the purchase of equipment, including computerized eye simulators, a laser injector, and a device for measuring the electrical resistance of cells.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Dean McGee Eye Institute celebrates its 50th anniversary this year, $800,000 in grants from Oklahoma-based Inasmuch Foundation and The Samuel Roberts Noble Foundation will help to fund the purchase of new equipment for academic and research initiatives https://t.co/2l5td0o02b
-
A Chinese study found that a tyrosine kinase inhibitor achieved both durable disease control and visual improvement in patients with epidermal growth factor receptor mutation-positive non–small-cell lung carcinoma that had metastasized to the choroid. https://t.co/MmFoP37c6M